Project Grant R56CA303722
Award Date 9/3/26
Completion Date 8/31/27
Dollars Obligated $134K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01655, USA
Similar Awards
- The National Cancer Institute awarded the University of Massachusetts Medical School $111,645 under the Cancer Research Manpower program (CFDA 93.398) on January 1, 2026, to support research training in basic and clinical cancer research. The award funds investigation of the functional role of CAMK2B loss in pancreatic cancer metastasis, examining how deletion of the calcium/calmodulin-dependent protein kinase II beta gene enhances tumor metastasis and creates an immunosuppressive tumor...
- The National Cancer Institute awarded University of Massachusetts Medical School $1.06 million on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to engineer multi-targeted nanoparticle-based immunotherapy for pancreatic cancer. The funded work develops lipid-based nanoparticles (NPs) carrying RAS pathway inhibitors (trametinib, palbociclib, or RMC-7977) and STING/TLR4 innate immune agonists, designed to home specifically to tumor cells and dendritic cells within the...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $633,089 to The University of Texas MD Anderson Cancer Center on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate a novel cell stress response mechanism in pancreatic ductal adenocarcinoma (PDAC) that enables cancer cells to adapt to adverse microenvironmental conditions and evade immune surveillance. The research will identify and characterize immunotherapeutic...
- The National Cancer Institute awarded a $1.21 million cooperative agreement to The Leland Stanford Junior University on August 7, 2026, to support research on tumor-immune coevolution during metastatic progression under the Cancer Biology Research program (CFDA 93.396). The research investigates how tumors and lymphocytes undergo reciprocal adaptive evolution throughout metastasis, with focus on mechanisms by which early-stage metastatic tumors exploit immune education within lymph nodes to...
- The National Cancer Institute awarded the University of Virginia $161,500 for cancer cell biology research on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396). The project develops methods to classify pancreatic ductal adenocarcinoma circulating tumor cells by single-cell deformability. Researchers will create a perfusable co-culture system with cancer-associated fibroblasts to generate pancreatic cancer cells expressing varied epithelial and mesenchymal states under shear...
- The National Cancer Institute, a division of the Department of Health and Human Services National Institutes of Health, awarded Health Research, Inc. (Roswell Park Division) $446,112 on July 3, 2026, under the Cancer Biology Research program (CFDA 93.396) to identify age-regulating breast cancer dormancy genes using C. elegans dauer models. The project investigates how chronological aging of dormant cancer cells drives metastatic relapse and reawakening after initial treatment. The recipient...
- The National Cancer Institute awarded the University of Massachusetts Medical School $142,251 on June 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to investigate the bidirectional tumor-host crosstalk in cachexia and pancreatic ductal adenocarcinoma. The award funds a K99/R00 early-career research project examining the molecular drivers of cachexia onset in pancreatic ductal adenocarcinoma, with particular focus on the role of parathyroid hormone-related protein (PTHRP) in...
- The National Cancer Institute, within the Department of Health and Human Services, awarded Dana-Farber Cancer Institute, Inc. $718,275 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate context-specific pathway dependencies for nuclear envelope proteins in brain cancer. The research addresses how nuclear envelope-associated proteins perform distinct biochemical functions across different cellular contexts in central nervous system cancers. The project uses an...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $606,749 on August 13, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate novel functions of cell cycle proteins in G1/S phase progression and cancer. The research examines the molecular roles of the cyclin B–CDK1 kinase complex in regulating cell cycle entry and DNA synthesis. Aim 1 uses mouse and human cells to identify the range of molecular functions played by cyclin B–CDK1 during G1/S phase....
- The National Cancer Institute, a division of the Department of Health and Human Services, awarded a cooperative agreement totaling $681,310 to The Trustees of Columbia University in the City of New York on June 24, 2026, under the Cancer Biology Research program (CFDA 93.396). The funded research investigates mechanisms that promote bone metastasis in prostate cancer, the major cause of death in metastatic prostate cancer patients. Columbia will use genetically-engineered mouse models (GEMMs) to...